<DOC>
	<DOCNO>NCT01422590</DOCNO>
	<brief_summary>1 . Explore pharmacodynamics - glucose - insulin - C-peptide - glucagon - intact GLP-1 - DPP-4 activity - CGMS ( continuous glucose monitor system ) 2 . Assess Safety - adverse event - clinical laboratory test - physical examination</brief_summary>
	<brief_title>Pharmacodynamics Mitiglinide/Sitagliptin Compared Mitiglinide Sitagliptin</brief_title>
	<detailed_description>Pharmacodynamic assessment - CGMS data obtain day 1 day 3 ( 48 hour ) - PD measure ( day 1 ) drug administration ( day 2 ) 1 . AUC glucose , insulin , C-peptide , glucagon , intact GLP-1 , DPP-4 activity 2 . MAGE ( mean amplitude glycemic excursion ) CGMS data</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Mitiglinide</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Male female patient type 2 diabetes mellitus 6.5 % ≤ HbA1c &lt; 9.0 % Stopped treatment sulfonylurea biguanide 8 week Stopped treatment antidiabetic agent 12 week 16 kg/m2 ≤ body mass index &lt; 30 kg/m2 Fasting glucose ≥ 200 mg/dL Required insulin therapy Patients neuropathy , retinopathy renopathy Contraindicated mitiglinide sitagliptin</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>sitagliptin</keyword>
	<keyword>mitiglinide</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Safety</keyword>
</DOC>